A Trial to Evaluate the Safety and Efficacy of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Extension



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:16 - 80
Updated:4/3/2019
Start Date:October 27, 2017
End Date:December 2020

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension

This is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlled
trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in
subjects with primary mitochondrial myopathy. This will be followed by an open-label
treatment extension.


PART 1:

Inclusion Criteria:

- Willing and able to provide a signed informed consent form prior to participation in
any trial-related procedures

- Agrees to adhere to the trial requirements for the length of the trial, including the
use of the elamipretide delivery system

- Subject is ≥ 16 and ≤ 80 years of age

- Diagnosed with PMM in the opinion of the investigator and confirmed by an Adjudication
Committee

- Woman of childbearing potential must agree to use a highly effective method of birth
control

Exclusion Criteria:

- Subject has myopathic signs and or/symptoms due to a neuropathic process or gait
problem that would interfere with the 6MWT, in the opinion of the Investigator

- Female who are pregnant, planning to become pregnant, or breastfeeding/lactating

- At Screening, the estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2

- Subject has undergone an in-patient hospitalization within the 30 days prior to the
Baseline Visit or has a planned hospitalization or a surgical procedure during the
trial.

- Subject has clinically significant cardiac disease or prior interventional procedure
and/or respiratory disease (medical history or current clinical findings) within 3
months of the Baseline Visit, in the opinion of the Investigator.

- Subject has QTc elongation (using the correction factor utilized at the clinical site)
defined as a QTc >450 msec in male subjects and >480 msec in female subjects.

- ECG evidence of acute ischemia, atrial fibrillation, or active conduction system
abnormalities with the exception of any of the following:

1. First degree AV-block

2. Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)

3. Right bundle branch block

- Subject has severe vision impairment that, in the opinion of the Investigator, may
interfere with their ability to complete all trial requirements

- Subject has a seizure disorder that, in the opinion of the Investigator, may interfere
with their ability to complete all trial requirements.

- Active malignancy or any other cancer from which the subject has been disease-free for
< 2 years.

- Subject has a solid organ transplant and/or is currently receiving treatment with
therapy for immunosuppression, in the opinion of the Investigator.

- Subject has been previously diagnosed with human immunodeficiency virus (HIV),
hepatitis B, or hepatitis C infection.

- Subject has a history of a systemic eosinophilic illness and/or an eosinophil count
>1,000 cells x10^6/L at the Screening Visit.

- Subject is currently participating or has participated in an interventional clinical
trial (i.e.,investigational product or device, stem cell therapy, gene therapy) within
30 days of the Baseline Visit; or is currently enrolled in a non-interventional
clinical trial (except for SPIMM-300) at the Baseline Visit which, in the opinion of
the Investigator, may be potentially confounding with results of the current trial
(e.g., exercise therapy trial).

- Subject has previously received elamipretide (MTP-131), for any reason.

- Subject has a history of active substance abuse during the year before the Baseline
Visit, in the opinion of the Investigator.

- Subject has any prior or current medical condition that, in the judgment of the
Investigator, would prevent the subject from safely participating in and/or completing
all trial requirements.

PART 2:

Continuation Criteria:

- Subjects must continue to be able and willing to adhere to the trial requirements.

- Subject is appropriate to continue in Part 2 (i.e. subject was compliant in Part 1),
in the opinion of the Investigator.

- Subject has not had a serious adverse event (SAE)/serious adverse device effect (SADE)
attributed to the elamipretide delivery system.

- Subject has not permanently discontinued the elamipretide delivery system.
We found this trial at
14
sites
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Phone: 412-692-3476
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
1 Perkins Square
Akron, Ohio 44308
(330) 543-1000
Phone: 330-543-4743
Akron Children's Hospital From humble beginnings as a day nursery in 1890, Akron Children
2040
mi
from 91732
Akron, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Phone: 617-724-7726
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Phone: 215-590-1934
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Atlanta, Georgia 30318
Phone: 404-883-2724
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Phone: 720-777-4690
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Cleveland, Ohio 44195
Phone: 216-444-0173
?
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-500-5372
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Houston, Texas
Phone: 832-822-1630
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Phone: 858-246-2288
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
95
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
Phone: 650-736-8166
329
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Phone: 206-987-0058
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Vancouver, British Colombia
Phone: 604-875-4111
?
mi
from 91732
Vancouver,
Click here to add this to my saved trials